Guggenheim Maintains Buy on Summit Therapeutics, Lowers Price Target to $38

Benzinga Newsdesk www.benzinga.com Negative 64.1%

Neg 64.1% Neu 0% Pos 0%

Guggenheim analyst Brad Canino maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the price target from $40 to $38.